SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for KRYS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 159.89M
March 31, 2026 155.20M
December 31, 2025 146.91M
September 30, 2025 136.75M
June 30, 2025 127.88M
March 31, 2025 120.35M
December 31, 2024 113.68M
September 30, 2024 107.16M
June 30, 2024 102.14M
March 31, 2024 100.42M
December 31, 2023 98.40M
September 30, 2023 97.67M
June 30, 2023 93.90M
March 31, 2023 85.86M
December 31, 2022 77.74M
September 30, 2022 66.57M
June 30, 2022 56.21M
March 31, 2022 48.15M
December 31, 2021 40.39M
September 30, 2021 32.27M
June 30, 2021 27.28M
Date Value
March 31, 2021 20.80M
December 31, 2020 15.06M
September 30, 2020 12.12M
June 30, 2020 8.998M
March 31, 2020 7.357M
December 31, 2019 6.463M
September 30, 2019 6.075M
June 30, 2019 5.676M
March 31, 2019 4.926M
December 31, 2018 4.156M
September 30, 2018 3.149M
June 30, 2018 2.829M
March 31, 2018 2.174M
December 31, 2017 1.563M
September 30, 2017 1.371M
June 30, 2017 0.714M
March 31, 2017 0.548M
December 31, 2016 0.402M
September 30, 2016 0.184M
June 30, 2016 0.103M
March 31, 2016 0.00

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
TG Therapeutics, Inc. 296.46M
Cytokinetics, Inc. 370.47M
Marker Therapeutics, Inc. 4.244M
Alnylam Pharmaceuticals, Inc. 1.318B
Exelixis, Inc. 533.92M